The decision of when to discontinue hepatitis B teratitis minor needs to be made on a case-by-case basis. For patients who do not have cirrhosis or progressive liver fibrosis and are unable or unwilling to continue lifelong treatment due to the risk or cost of associated adverse events, an attempt to discontinue treatment may be made if the following criteria are met: HBV DNA undetectable by PCR for > 3 years; and agreement to close monitoring for at least 1 year, i.e., review of liver function once a month for the first 6 months, and testing for HBV DNA every 3 months; and review of liver function and HBV DNA once a month for the next 6 months; and review of liver function and HBV DNA once a month for every 3 months. Liver function and HBV DNA should be checked every 3 months for the first 6 months, and every 3 months for the second 6 months, after which the frequency of monitoring can be reduced to every 6-12 months if the patient maintains inactive carrier status. Hepatitis B minor triple yang patients who go to the hospital for liver function tests, HBV~DNA tests and ultrasound tests may have abnormal liver function. If the condition is allowed to develop, it may progress to cirrhosis, a condition that leads to an increased likelihood of liver tumors and liver ascites. Usually this condition cannot be stopped. If a patient with minor triple yang can be sure that his condition is stable after several tests, he still needs to go to the hospital regularly for relevant checkups, so as to avoid the recurrence of the condition and affecting his friends and family around him.